流感病毒M2e蛋白的制备及其抗甲型流感病毒研究
|
摘要
M2 (Matrix protein 2,M2)蛋白是流感病毒主要的膜蛋白之一。研究发现,针对M2蛋白的单克隆抗体在细胞培养中具有抑制流感病毒复制的功能。进一步证明,M2蛋白胞外功能区(Extracellular domain of M2 protein,M2e)诱导机体产生的抗体同样具有保护性。目前,在人群中流行的所有甲型流感病毒,其M2蛋白的胞外区都未发现存在明显差异,认为M2e在流感病毒间是高度保守的。因此,M2e蛋白被认为是可刺激机体对不同流感变异株都产生具有交叉保护效果的保护性抗原。鉴于此,本研究围绕M2e蛋白进行了如下工作。
利用基因重组技术构建了毕赤酵母真核表达载体pPICZαC-HSA/M2e,电转化毕赤酵母X-33,SDS-PAGE筛选出能够稳定高效分泌表达重组HSA/M2e的工程菌。重组蛋白经AKTA explorer多功能纯化系统纯化,Western Blot方法进一步证明表达的重组HSA/M2e分别具有HSA和M2e的活性;蛋白质N-端测序证明表达的重组HSA/M2e与天然HSA N-端氨基酸序列相同。利用80 L发酵罐进行HSA/M2e中试规模发酵,并对其发酵条件进行优化,HSA/M2e表达量可达到1080 mg/L,同时建立了一种分离纯化HSA/M2e的新方法。
用纯化的融合蛋白HSA/M2e免疫BALB/c小鼠三次后,用甲型流感病毒H1N1和H3N2对小鼠滴鼻进行攻击,从小鼠的肺部病毒滴度、体重变化及死亡率等几个方面检测M2e蛋白的免疫效果。结果表明,融合蛋白HSA/M2e能显著减少小鼠体重的丢失和降低小鼠的死亡率,保护小鼠抵抗甲型流感病毒H1N1和H3N2的攻击。
本研究创新之处:1)首次在毕赤酵母中高效表达了融合蛋白HSA/M2e;2)利用80 L发酵罐进行了HSA/M2e毕赤酵母工程菌的中试规模发酵,对其表达条件进行了优化,建立了一种适用于大规模分离纯化HSA/M2e的方法,证明应用毕赤酵母表达系统表达的重组蛋白HSA/M2e具有HSA和M2e的活性;3)融合蛋白HSA/M2e能显著地减少小鼠体重的丢失和降低小鼠的死亡率,并降低肺部病毒滴度,保护小鼠抵抗甲型流感病毒的攻击。
Influenza virus is the pathogen of influenza, which often swept the global and is a kind of highly contagious disease with the high lethality rate among all of the infectious diseases. The best way to prevent influenza virus at the present time is vaccination. All commercial human influenza vaccines presently available contain hemagglutinin and neuraminidase as their main viral antigen. Influenza hemagglutinin and neuraminidase, are large glycoproteins, well accessible on the viral membrane and highly immunogenic which can induce anti-HA and anti-NA in host. Although they can offer fine protection, they have one considerable drawback: antigenic drift and antigenic shift which cause the variation of influenza virus and may result in a pandemic. The conventional influenza vaccine must be adapted almost every year to follow the antigenic drift and shift of the virus and the antibodies exist in human body induced by vaccination or exposure to previously circulating virus could not efficiently prevent the infection of mutated strains. It is much inconvenient for influenza vaccine preparation, and if vaccine doesn’t match with prevalent strain, it can’t produce enough immunoprotection.
A universal vaccine, which protects effectively against all influenza A strains and provides long-lasting immunity, will definitely be an attractive solution to overcome the threat of this promiscuous virus. Except HA and NA, the matrix protein M2 is also a transmembrane protein of the influenza A virus. Although the protein plays an important role in virus replication, it is much smaller, only 97 amino acids long.Among these amino acids, 24 amino acids at the N terminus are exposed at the membrane surface, 19 amino acids span the lipid bilayer, whereas the remaining 54 residues are located on the cytoplasmic side of the membrane. The extracellular domain of the influenza M2 protein (M2e) remained nearly invariable since the first human influenza A virus strain A/WS/33(H1N1) was isolated in 1933. Several studies have demonstrated that influenza vaccines based on M2e exhibited effective protective immunity, importantly, this protective immunity caused by M2e is broad-spectrum, make it become one of the important target genes in the study of general vaccine.
Human serum albumin (HSA) is the majority component of serum, which is involved in maintenance of osmolarity and plasma volume. It consists of a single non-glycosylated polypeptide chain of 585 amino acids forming a globular protein. It is a natural carrier involved in the endogenous transport and delivery of various natural as well as therapeutic molecules and has a long half-life of 19 days in human beings. After fusing with human serum albumin, the fusion protein can reduce its bioavailability and prolong its half-time in vivo to boost therapeutic effect. Meanwhile, HSA could achive high-level expression in P. pastoris and hybrid protein was less in supernatant so it was easy to achieve large-scale production.
However, M2e could only induce much lower immunologic reaction since it is a small peptide of 23 amino acids and the molecular weight is small. In this study, we aim to modify pPICZαC-HSA as a vaccine vector and link the M2e-peptide to HSA. Our strategy is to use HSA to boost the immunogenicity of M2e peptide.
The contents of this paper are focused on the following parts:①Constructing expression vector pPICZαC-HSA/M2e, transforming it into Pichia pastoris via electroporation and screening the engineering strains secreting the protein at high levels steadily.②Studying the large-scale fermentation process of HSA/M2e in 80L fermentor, optimizing the main parameters, and creating a new method for large-scale purification of HSA/M2e.③Purified HSA/M2e as a vaccine was administered to mice and observed the M2e-specific immune response induced by HSA/M2e and its protection against influenza virus challenge.
1. Construction of Pichia pastoris expression system for HSA/M2e:
1.1 Construction expression vector pPICZαC-HSA/M2e:
HSA gene was obtained by RT-PCR from liver, then it was inserted into pMD18-T vector. Results of DNA sequence analysis of the recombinant vector pMD18-T-HSA demonstrated that cDNA encoding human HSA was correctly inserted into pMD18-T vector and the sequence was consistent with that logged in GenBank (accession No. NM_000477). After confirmation by sequencing, BstbI and kpnI target sites were added using expression primers by PCR. After digestion with BstBI and KpnI, it was ligated into vector pPICZαC which was also digested with BstBI and KpnI. The plasmid was named pPICZαC-HSA. Two oligonucleotides of M2e were synthesized which had restriction endonuclease cohesive ends of Eco81I and KpnI, and DNA fragment after two oligonucleotides annealing was ligated into vector pPICZαC-HSA which was digested with Eco81I and KpnI. The plasmid was named pPICZαC-HSA/M2e. After confirmation by endonuclease digestion assay and sequencing, the expression vector pPICZαC-HSA/M2e was linearized and transformed into Pichia pastoris X-33 via electroporation.
1.2 Screening and identification of the transformed Pichia pastoris
Transformed yeasts were plated on YPD plates containing Zeocin to isolate Zeocin -resistant clones. After clones were cultured for 72 hours at 30℃, 10 single clones were picked into culture. Then the genomic DNA of the transformed yeasts were extracted to perform PCR using the expression primers. Yeast clones tested positively by PCR were proliferated and then HSA/M2e was induced with 0.5% methanol. The supernatant of fermentation was identified by SDS-PAGE and Western Blot and the highest level strain was screened. Western Blot results indicated that the recombinant HSA/M2e was identical with HSA and M2e. And the HSA/M2e protein was purified by AKTA explorer using Mono S cation-exchange chromatography, ultrafiltration and Mono Q anion-exchange chromatography. The purity coefficient of HSA/M2e could be more than 95% and amino acid sequencing could prove the 9 N terminal amino acid were identical with natural HSA.
2. Studies on large-scale fermentation and purification process of HSA/M2e
2.1 Studies on large-scale fermentation process of HSA/M2e
There are many advantages as a kind of expression host of Pichia pastoris, and it’s very suitable for large-scale expression of the extraneous proteins. We further explored the large-scale fermentation process of HSA/M2e in 80L fermentor. The study was focused mainly on pH value, culture medium, dissolved oxygen, methanol feeding speed, initial biomass and etc. We could confirm that the best conditions for fermentation were as follows: in the FM21 medium (including 0.5% peptone) of pH 5.5, when a cell yield of 200 g/L wet weight was achieved, methanol induction phase began. In the fermentation broth of pH5.5, DO between 20~30% and the supply speed of methanol is 11ml/h/L initial fermentation volume, after methanol induction for about 42 h the expression level of HSA/M2e peaked. The concentration of HSA/M2e in the broth can reach 1080 mg/L.
2.2 A new method to purify HSA/M2e at large-scale
The fermentation supernatant was purified with SP Sepharose XL cation exchange chromatography and sourceTM 30 RPC hydrophobic chromatography, then the eluate was distilled to condense HSA/M2e. The degree of purity could be more than 93% and the yield coefficient was higher than 65%.
3. Studies on animal vaccination with HAS/M2e and challenge experiments
3.1 study on animal vaccination with HSA/M2e
6~8-week-old male BALB/c mice were divided into 3 groups randomly, 9 mice per group. We gave a total of three injections intraperitoneally, at 2-week interval. PBS, HAS/M2e and inactivated split influenza vaccine were injected into each group. We obtained blood samples 1 day before the first injection and 1 week after each of the three subsequent injections. We analyzed the serum by ELISA to identify IgG antibodies directed against M2e. The anti-M2e titer in HSA/M2e group and vaccine group were higher than that in PBS group (P<0.05). The anti-M2e was arised from the second week after immunization and rased with the increasing of the number of immunization. The titer was highest in the eighth week.
In order to estimate the cellular immunity, we got the splenic lymphocyte of mice 7 days after the last immunization to do experiment of detection of T lymphocyte subtype, lymphocyte transformation and IFN-γ. The results of flow cytometric analysis showed that cell population of CD4+ and CD8+ T lymphocyte of recombination protein group and influenza vaccine group were higher than that of PBS group, but the cellular immunity of influenza vaccine group was excellent especially. The results of lymphocyte transformation demonstrated that the SI index of recombination protein group was higher than that of PBS group , but lower than that of influenza vaccine group (P<0.01) when stimulated with ConA and antigen. The results showed that the numbers of IFN-γ-secreting cell of all experimental groups are more than that of PBS control group evidently (P<0.05), and the numbers of IFN-γ-secreting cell of influenza vaccine group are higher than that of recombination protein .
3.2 study on challenge experiment with influenza A virus
Mice were infected intranasally (i.n.) with H1N1 and H3N2 virus for about 7 days after the last immunization. Mice were sacrificed 6 days after infection. We got lung of mice and weighed it to calculate the index of lung and inhibitory ratio of the index of lung. The index of lung of PBS group was obviously higher than that of recombination protein group and influenza vaccine group (P<0.05), which were (14.28±1.21) mg/g and (13.89±1.47) mg/g, while recombination protein group and influenza vaccine group were only (11.03±1.08) mg/g, (11.18±1.32) mg/g and (10.45±1.13) mg/g, (10.32±1.40) mg/g, respectively. There was no significant statistical difference between all experimental groups and PBS group (P <0.05).
The lung of mice were made to cell suspension and the lung virus titers were determined on MDCK cells. The results showed that the lung virus titers of PBS group were higher than that of recombination protein group and influenza vaccine group, significantly (P<0.05), but he lung virus titers of recombination protein group and influenza vaccine group were no significant difference.
Histopathological changes of lung tissues: The lung was taken out and sliced in the normal regulations slice and dyed with HE. The morphological changes of lung tissue was observed under optical microscope. The lung volume of mice of PBS group increased and engorged, while the lungs of normal mice were pink and smooth. About the lung tissues of recombination protein group and influenza vaccine group, the structures of lung alveolus were good and infiltrative phlegmasia cells were less. While many phlegmasia secretion substance and phlegmasia cells infiltrated in lung alveolus of mice of PBS group and the structures of lung alveolus were mostly destroyed.
The weight and the number of death of mice were observed 14 days after the virus challenge. The results demonstrated that the weight of PBS group decreased obviously to die after the challenge and all mice of PBS group died after about 10 days .While the weight of recombination protein group and influenza vaccine group decreased in a short time, then recoverd to normal level gradually . The mortality of mice of PBS group were about 87.5% and 100%, while the mortality of recombination protein group were 25%, 37.5% and influenza vaccine group only were 12.5%, respectively. So we consider recombination protein and influenza vaccine could protect the mice against the challenge of the influenza virus.
To sum up, in this study we constructed and screened the high-level expression HSA/M2e Pichia pastoris engineering strains, and obtained a high level expression with a yield of 1080 mg/L in a 80 L fermentor by optimizing the main parameters affecting fermentation such as pH, DO and so on.We also established a new method for large-scale fermentation and purification of HSA/M2e in Pichia pastoris. After immunization for three times, the purified HSA/M2e could induce specific cellular immunity and humoral immunity in the BALB/C mice, which could protect the mice against the challenge of lethal dose of H1N1 and H3N2 virus. Our study made the foundation of further exploration on the broad-spectrum influenza vaccine providing cross-protection against different influenza variants.
利用基因重组技术构建了毕赤酵母真核表达载体pPICZαC-HSA/M2e,电转化毕赤酵母X-33,SDS-PAGE筛选出能够稳定高效分泌表达重组HSA/M2e的工程菌。重组蛋白经AKTA explorer多功能纯化系统纯化,Western Blot方法进一步证明表达的重组HSA/M2e分别具有HSA和M2e的活性;蛋白质N-端测序证明表达的重组HSA/M2e与天然HSA N-端氨基酸序列相同。利用80 L发酵罐进行HSA/M2e中试规模发酵,并对其发酵条件进行优化,HSA/M2e表达量可达到1080 mg/L,同时建立了一种分离纯化HSA/M2e的新方法。
用纯化的融合蛋白HSA/M2e免疫BALB/c小鼠三次后,用甲型流感病毒H1N1和H3N2对小鼠滴鼻进行攻击,从小鼠的肺部病毒滴度、体重变化及死亡率等几个方面检测M2e蛋白的免疫效果。结果表明,融合蛋白HSA/M2e能显著减少小鼠体重的丢失和降低小鼠的死亡率,保护小鼠抵抗甲型流感病毒H1N1和H3N2的攻击。
本研究创新之处:1)首次在毕赤酵母中高效表达了融合蛋白HSA/M2e;2)利用80 L发酵罐进行了HSA/M2e毕赤酵母工程菌的中试规模发酵,对其表达条件进行了优化,建立了一种适用于大规模分离纯化HSA/M2e的方法,证明应用毕赤酵母表达系统表达的重组蛋白HSA/M2e具有HSA和M2e的活性;3)融合蛋白HSA/M2e能显著地减少小鼠体重的丢失和降低小鼠的死亡率,并降低肺部病毒滴度,保护小鼠抵抗甲型流感病毒的攻击。
Influenza virus is the pathogen of influenza, which often swept the global and is a kind of highly contagious disease with the high lethality rate among all of the infectious diseases. The best way to prevent influenza virus at the present time is vaccination. All commercial human influenza vaccines presently available contain hemagglutinin and neuraminidase as their main viral antigen. Influenza hemagglutinin and neuraminidase, are large glycoproteins, well accessible on the viral membrane and highly immunogenic which can induce anti-HA and anti-NA in host. Although they can offer fine protection, they have one considerable drawback: antigenic drift and antigenic shift which cause the variation of influenza virus and may result in a pandemic. The conventional influenza vaccine must be adapted almost every year to follow the antigenic drift and shift of the virus and the antibodies exist in human body induced by vaccination or exposure to previously circulating virus could not efficiently prevent the infection of mutated strains. It is much inconvenient for influenza vaccine preparation, and if vaccine doesn’t match with prevalent strain, it can’t produce enough immunoprotection.
A universal vaccine, which protects effectively against all influenza A strains and provides long-lasting immunity, will definitely be an attractive solution to overcome the threat of this promiscuous virus. Except HA and NA, the matrix protein M2 is also a transmembrane protein of the influenza A virus. Although the protein plays an important role in virus replication, it is much smaller, only 97 amino acids long.Among these amino acids, 24 amino acids at the N terminus are exposed at the membrane surface, 19 amino acids span the lipid bilayer, whereas the remaining 54 residues are located on the cytoplasmic side of the membrane. The extracellular domain of the influenza M2 protein (M2e) remained nearly invariable since the first human influenza A virus strain A/WS/33(H1N1) was isolated in 1933. Several studies have demonstrated that influenza vaccines based on M2e exhibited effective protective immunity, importantly, this protective immunity caused by M2e is broad-spectrum, make it become one of the important target genes in the study of general vaccine.
Human serum albumin (HSA) is the majority component of serum, which is involved in maintenance of osmolarity and plasma volume. It consists of a single non-glycosylated polypeptide chain of 585 amino acids forming a globular protein. It is a natural carrier involved in the endogenous transport and delivery of various natural as well as therapeutic molecules and has a long half-life of 19 days in human beings. After fusing with human serum albumin, the fusion protein can reduce its bioavailability and prolong its half-time in vivo to boost therapeutic effect. Meanwhile, HSA could achive high-level expression in P. pastoris and hybrid protein was less in supernatant so it was easy to achieve large-scale production.
However, M2e could only induce much lower immunologic reaction since it is a small peptide of 23 amino acids and the molecular weight is small. In this study, we aim to modify pPICZαC-HSA as a vaccine vector and link the M2e-peptide to HSA. Our strategy is to use HSA to boost the immunogenicity of M2e peptide.
The contents of this paper are focused on the following parts:①Constructing expression vector pPICZαC-HSA/M2e, transforming it into Pichia pastoris via electroporation and screening the engineering strains secreting the protein at high levels steadily.②Studying the large-scale fermentation process of HSA/M2e in 80L fermentor, optimizing the main parameters, and creating a new method for large-scale purification of HSA/M2e.③Purified HSA/M2e as a vaccine was administered to mice and observed the M2e-specific immune response induced by HSA/M2e and its protection against influenza virus challenge.
1. Construction of Pichia pastoris expression system for HSA/M2e:
1.1 Construction expression vector pPICZαC-HSA/M2e:
HSA gene was obtained by RT-PCR from liver, then it was inserted into pMD18-T vector. Results of DNA sequence analysis of the recombinant vector pMD18-T-HSA demonstrated that cDNA encoding human HSA was correctly inserted into pMD18-T vector and the sequence was consistent with that logged in GenBank (accession No. NM_000477). After confirmation by sequencing, BstbI and kpnI target sites were added using expression primers by PCR. After digestion with BstBI and KpnI, it was ligated into vector pPICZαC which was also digested with BstBI and KpnI. The plasmid was named pPICZαC-HSA. Two oligonucleotides of M2e were synthesized which had restriction endonuclease cohesive ends of Eco81I and KpnI, and DNA fragment after two oligonucleotides annealing was ligated into vector pPICZαC-HSA which was digested with Eco81I and KpnI. The plasmid was named pPICZαC-HSA/M2e. After confirmation by endonuclease digestion assay and sequencing, the expression vector pPICZαC-HSA/M2e was linearized and transformed into Pichia pastoris X-33 via electroporation.
1.2 Screening and identification of the transformed Pichia pastoris
Transformed yeasts were plated on YPD plates containing Zeocin to isolate Zeocin -resistant clones. After clones were cultured for 72 hours at 30℃, 10 single clones were picked into culture. Then the genomic DNA of the transformed yeasts were extracted to perform PCR using the expression primers. Yeast clones tested positively by PCR were proliferated and then HSA/M2e was induced with 0.5% methanol. The supernatant of fermentation was identified by SDS-PAGE and Western Blot and the highest level strain was screened. Western Blot results indicated that the recombinant HSA/M2e was identical with HSA and M2e. And the HSA/M2e protein was purified by AKTA explorer using Mono S cation-exchange chromatography, ultrafiltration and Mono Q anion-exchange chromatography. The purity coefficient of HSA/M2e could be more than 95% and amino acid sequencing could prove the 9 N terminal amino acid were identical with natural HSA.
2. Studies on large-scale fermentation and purification process of HSA/M2e
2.1 Studies on large-scale fermentation process of HSA/M2e
There are many advantages as a kind of expression host of Pichia pastoris, and it’s very suitable for large-scale expression of the extraneous proteins. We further explored the large-scale fermentation process of HSA/M2e in 80L fermentor. The study was focused mainly on pH value, culture medium, dissolved oxygen, methanol feeding speed, initial biomass and etc. We could confirm that the best conditions for fermentation were as follows: in the FM21 medium (including 0.5% peptone) of pH 5.5, when a cell yield of 200 g/L wet weight was achieved, methanol induction phase began. In the fermentation broth of pH5.5, DO between 20~30% and the supply speed of methanol is 11ml/h/L initial fermentation volume, after methanol induction for about 42 h the expression level of HSA/M2e peaked. The concentration of HSA/M2e in the broth can reach 1080 mg/L.
2.2 A new method to purify HSA/M2e at large-scale
The fermentation supernatant was purified with SP Sepharose XL cation exchange chromatography and sourceTM 30 RPC hydrophobic chromatography, then the eluate was distilled to condense HSA/M2e. The degree of purity could be more than 93% and the yield coefficient was higher than 65%.
3. Studies on animal vaccination with HAS/M2e and challenge experiments
3.1 study on animal vaccination with HSA/M2e
6~8-week-old male BALB/c mice were divided into 3 groups randomly, 9 mice per group. We gave a total of three injections intraperitoneally, at 2-week interval. PBS, HAS/M2e and inactivated split influenza vaccine were injected into each group. We obtained blood samples 1 day before the first injection and 1 week after each of the three subsequent injections. We analyzed the serum by ELISA to identify IgG antibodies directed against M2e. The anti-M2e titer in HSA/M2e group and vaccine group were higher than that in PBS group (P<0.05). The anti-M2e was arised from the second week after immunization and rased with the increasing of the number of immunization. The titer was highest in the eighth week.
In order to estimate the cellular immunity, we got the splenic lymphocyte of mice 7 days after the last immunization to do experiment of detection of T lymphocyte subtype, lymphocyte transformation and IFN-γ. The results of flow cytometric analysis showed that cell population of CD4+ and CD8+ T lymphocyte of recombination protein group and influenza vaccine group were higher than that of PBS group, but the cellular immunity of influenza vaccine group was excellent especially. The results of lymphocyte transformation demonstrated that the SI index of recombination protein group was higher than that of PBS group , but lower than that of influenza vaccine group (P<0.01) when stimulated with ConA and antigen. The results showed that the numbers of IFN-γ-secreting cell of all experimental groups are more than that of PBS control group evidently (P<0.05), and the numbers of IFN-γ-secreting cell of influenza vaccine group are higher than that of recombination protein .
3.2 study on challenge experiment with influenza A virus
Mice were infected intranasally (i.n.) with H1N1 and H3N2 virus for about 7 days after the last immunization. Mice were sacrificed 6 days after infection. We got lung of mice and weighed it to calculate the index of lung and inhibitory ratio of the index of lung. The index of lung of PBS group was obviously higher than that of recombination protein group and influenza vaccine group (P<0.05), which were (14.28±1.21) mg/g and (13.89±1.47) mg/g, while recombination protein group and influenza vaccine group were only (11.03±1.08) mg/g, (11.18±1.32) mg/g and (10.45±1.13) mg/g, (10.32±1.40) mg/g, respectively. There was no significant statistical difference between all experimental groups and PBS group (P <0.05).
The lung of mice were made to cell suspension and the lung virus titers were determined on MDCK cells. The results showed that the lung virus titers of PBS group were higher than that of recombination protein group and influenza vaccine group, significantly (P<0.05), but he lung virus titers of recombination protein group and influenza vaccine group were no significant difference.
Histopathological changes of lung tissues: The lung was taken out and sliced in the normal regulations slice and dyed with HE. The morphological changes of lung tissue was observed under optical microscope. The lung volume of mice of PBS group increased and engorged, while the lungs of normal mice were pink and smooth. About the lung tissues of recombination protein group and influenza vaccine group, the structures of lung alveolus were good and infiltrative phlegmasia cells were less. While many phlegmasia secretion substance and phlegmasia cells infiltrated in lung alveolus of mice of PBS group and the structures of lung alveolus were mostly destroyed.
The weight and the number of death of mice were observed 14 days after the virus challenge. The results demonstrated that the weight of PBS group decreased obviously to die after the challenge and all mice of PBS group died after about 10 days .While the weight of recombination protein group and influenza vaccine group decreased in a short time, then recoverd to normal level gradually . The mortality of mice of PBS group were about 87.5% and 100%, while the mortality of recombination protein group were 25%, 37.5% and influenza vaccine group only were 12.5%, respectively. So we consider recombination protein and influenza vaccine could protect the mice against the challenge of the influenza virus.
To sum up, in this study we constructed and screened the high-level expression HSA/M2e Pichia pastoris engineering strains, and obtained a high level expression with a yield of 1080 mg/L in a 80 L fermentor by optimizing the main parameters affecting fermentation such as pH, DO and so on.We also established a new method for large-scale fermentation and purification of HSA/M2e in Pichia pastoris. After immunization for three times, the purified HSA/M2e could induce specific cellular immunity and humoral immunity in the BALB/C mice, which could protect the mice against the challenge of lethal dose of H1N1 and H3N2 virus. Our study made the foundation of further exploration on the broad-spectrum influenza vaccine providing cross-protection against different influenza variants.
引文
[1]陆德源.医学微生物学[M].北京:人民卫生出版社, 2002.
[2]金奇.医学分子病毒学[M].北京:科学出版社, 2001.
[3] Fouchier RAM, Munster V, Wallensten A, et al. Characterization of a noval influenza A virus hemagglutinin subtybe (H16) obtained from black-headed gulls[J]. JVirol, 2005, 79(5):2814-2822.
[4] Maeda Y, Horimoto T, Kawaoka Y. Classification and genome structure of influenza virus[J]. Nippon Rinsho, 2003, 61(11):1897-1901.
[5] Joost Haasnoot PC, Cupac D, Berkhout B.Inhibition of virus replication by RNA interference[J]. J Biomed Sci, 2003, 10(6):607-616.
[6] Shvartsman DE, Kotler M, Tall RD, et al. Differently anchored influenza hemagglutinin mutants display distinct inter-action dynamics with mutual rafts[J]. J Cell Biol, 2003, 163 (4):879-888.
[7] Steinhauer DA, Skehel JJ. Genetics of influenza viruses[J]. Annu Rev Genet, 2002, 36:305-332.
[8] Skehel JJ, Wiley DC. Influenza haemagglutinin[J]. Vaccine, 2002, 20(suppl): s51-s54.
[9] Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine[J]. Vaccine, 1999, 17(15-16):2073-2080.
[10] Nakajima K. The mechanism of antigenic shift and drift of human influenza virus[J]. Nippon Rinsho, 2003, 61(11):1897-1903.
[11]宋晓国,王国华,朱翠侠,等.甲型H1N1流感病毒NA、PB2和PA表位抗原区段的克隆和表达[J].生物技术通讯, 2010, 21(1):17-21.
[12] Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009[J]. MMWR Morb Mortal Wkly Rep, 2009, 58(17):467-470.
[13]高和.流感疫苗的研究与应用[J].解放军保健医学杂志, 2004, 6(4):244-245.
[14]陈秀英,戴宏琛.流感的流行及防治的现状研究[J].预防医学情报杂志,2002, 18(4):300-301.
[15] Brede HD. Influenza vaccines[J]. Int Arch Allergy Immunol, 1995, 108(4): 318-320.
[16] Nicholson KG, Wood JM, Zambon M, et al. Influenza[J]. Lancet, 2003, 362 (9397):1733-1745.
[17]苏晓晓,许可,金红.流感病毒疫苗研究的新进展[J].日本医学介绍, 2006, 27(9):424-426.
[18] World Health Organization. Recommendations for production and control of influenza vaccine (inactivated) [C]. 54th Meeting of the WHO Expert Commtttee on Biological Standardization, November 17-21, 2003.
[19]张延龄,张辉.疫苗学[M].北京:科学出版社, 2006.
[20]戚凤春,盛军.流感疫苗的研究进展[J].中国生物制品学杂志, 2004, 17(3): 190-192.
[21] Tolpin MD, Massicot JG, Mullinix MG, et al. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo[J]. Virology, 1981, 112 (2):505-517.
[22] Wareing MD, Tannock GA. Live attenuated vaccines against influenza;an historical review[J]. Vaccine, 2001, 19(25-26):3320-3330.
[23]张英伟,李卫东,马娜,等.以重配技术制备H1N1流感病毒Vero细胞适应株[J].中国生物制品学杂志, 2009, 22(6):529-532.
[24] Treanor JJ, Tierney EL, London WT, et al. Characterisation of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during in vitro production of avian-human reassortant vaccine viruses and after replication in humans and primates[J]. Vaccine, 1991, 9(7):495-501.
[25] Klimov AI, Cox NJ, Yotov WV, et al. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57(H2N2) virus[J]. Virology, 1992, 186(2):795-797.
[26] Belshe RB, Nichol KL, Black SB, et al. Safety,efficacy and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years[J]. Clin Infect Dis, 2004, 39(7):920-927.
[27] Beyer WE, Palache AM, de Jong JC, et al.Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemicantibody response, and vaccine efficacy: A meta-analysis[J]. Vaccine, 2002, 20 (9-10):1340-1353.
[28] Jefferson T, Smith S, Demicheli V, et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children[J]. Lancet, 2005, 365(9461):773-780.
[29] Kemble G, Greenberg H. Novel generations of influenza vaccines[J]. Vaccine, 2003, 21(16):1789-1795.
[30] Romanova JR, Tannock GA, Alexandrova GI. Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses[J]. Vaccine, 1997, 15(6-7):653-658.
[31] Harper SA, Fukuda K, Cox NJ, et al. Using live,attenuated influenza vaccine for prevention and control of influenza:supplemental recommendations of the Advisory Committee on Immunization Practices(ACIP) [J]. MMWR Recomm Rep, 2003, 52 (RR-13):1-8.
[32] Masic A, Babiukt LA, Zhou Y. Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs[J]. J Gen Virol, 2009, 90(Pt2): 375-385.
[33] Garcy’a-Sastre A, Egorov A, Matassov D, et al. Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems[J]. Virology, 1998, 252(2): 324-330.
[34] Watanabe T, Watanabe S, Neumann G, et al. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like Particles[J]. J Virol, 2002, 76(2):767-773.
[35] Talon J, Salvatore M, O′Neill RE, et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach[J]. Proc Natl Acad Sci USA, 2000, 97(8):4309-4314.
[36] Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein[J]. Science, 1993, 259(5102):1745-1749.
[37] Robinson HL, Hunt LA, Webster R G. Protection against a lethal influenza virus challenge by immunization with a hemagglutinin-expressing plasmid DNA[J]. Vaccine, 1993, 11(9):957-960.
[38] Mccluskie MJ, Davis HL. Novel strategies using DNA for the induction ofmucosal immunity[J]. Crit Rev Immunnol, 1999, 19(4):303-329.
[39] Ulmer JB, Deck RR, Dewitt CM, et al. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines[J]. Vaccine, 1994, 12 (16):1541-1544.
[40] Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations[J]. Proc Natl Acad Sci USA, 1993, 90(24):11478-11482.
[41] Tao P, Luo M, Pan Z, et al. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice[J]. Antiviral Res, 2009, 81(3):253-260.
[42] Ulmer JB, Fu TM, Deck RR, et al. Protective CD4+ and CD8+ T cells against influenza induced by vaccination with nucleoprotein DNA[J]. J Virol, 1998, 72(7):5648-5653.
[43] Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines[J]. Vaccine, 200l, 19(6):2666-2672.
[44]王斌. ISCOMATRIXTM佐剂:细胞和体液免疫应答的有效诱导剂[J].国外医学:预防、诊断、治疗用生物制品分册, 2005, 28(5):204-207.
[45] Watanabe I, Hagiwara Y, Kadowaki SE, et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K) [J]. Vaccine, 2002, 20 (29-30):3443-3455.
[46] Glueck R. Review of intranasal influenza vaccine[J]. Adv Drug Deli Rev, 2001, 51(1-3):203-211.
[47]邹丽容,方芳,陈则. IL-12增强流感血凝素DNA疫苗在小鼠中抗流感作用[J].微生物学杂志, 2004, 24(5):11-16.
[48] Hayashi M, Satou E, Ueki R, et al. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator[J]. Biochem Biophys Res Commun, 2005, 329(1):230-236.
[49] Li GX, Tian ZJ, Tong GZ, et al. Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus[J]. Res Vet Sci, 2009, 86(3): 406-413.
[50] Watabe S, Xin KQ, Ihata A, et al. Protection against influenza virus challenge bytopical application of influenza DNA vaccine[J]. Vaccine, 2001, 19(31): 4434 -4444.
[51] Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization:the possible role of DNA uptake in the induction of cellular immunity to viruses[J]. Proc Natl Acad Sci USA, 1994, 91(20):9519-9523.
[52] Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors[J]. DNA Cell Biol, 1993, 12(9):777-783.
[53] Robinson HL, Boyle CA, Feltquate DM, et al. DNA immunization for influenza virus:studies using hemagglutinin- and nucleoprotein-expressing DNAs[J]. J Infect Dis, 1997, 176(suppl 1):S50-S55.
[54] Chen Z, Yoshikawa T, Kadowaki S, et al. Protection and antibody response in different strains of mouse immunized with plasmid DNAs encoding influenza virus hemagglutinin, neuraminidase and nucleoprotein[J]. J Gen Virol, 1999, 80(10):2559-2564.
[55] Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface[J]. Cell, 1985, 40(3): 627-633.
[56] Sakaguchi T, Tu Q, Pinto LH, et a1. The active aligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer[J]. Proc Natl Acad Sci USA, 1997, 94(5):5000-5004.
[57] Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity[J]. Cell, 1992, 69(3):517-528.
[58] Czabotar PE, Martin SR, Hay AJ. Studies of structural changes in the M2 proton channel of influenza A virus by tryptophan fluorescence[J].Virus Res, 2004, 99(1):57-61.
[59] Duong-Ly KC, Nanda V, Degrado WF, et al. The conformation of the pore region of the M2 proton channel dependson lipid bilayer environment[J]. Protein Sci, 2005, 14(4):856-861.
[60] Kass I, Arkin IT. How pH opens a H+ channel: the gating mechanism of infiuenza A M2[J]. Structure, 2005, 13(12):1789-1798.
[61] Wu Y, Voth GA. A computational study of the closed and open states of the influenza a M2 proton channel[J]. Biophys J, 2005, 88(4):2402-2411.
[62] Castrucci MR, Kawaoka Y. Reverse genetics system for generation of an influenza a virus mutant containing a deletion of the carboxylterminal residue of M2 protein[J]. J Virol, 1995, 69(5):2725-2728.
[63] Monto AS. The role of antivirals in the control of influenza[J]. Vaccine, 2003, 21(16):1796-1800.
[64] Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection[J]. J Virol, 1988, 62(5): 1508-1512.
[65] Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults:systematic review[J]. Lancet, 2006, 367(24):303-313.
[66] Kitahori Y, Nakano M, Inoue Y. Frequency of amantadine-resistant influenza A virus isolated from 2001-02 to 2004-05 in Nara Prefecture[J]. Jpn J Infect Dis, 2006, 59(3):197-199.
[67] Masuda H, Suzuki H, Oshitani H, et al. Incidence of amantadine-resistant influenza a viruses in sentinel surveillance sites and nursing homes in Niigata, Japan[J]. Microbiol Immunol, 2000, 44 (10):833-839.
[68] Fiers W, Neirynck S, Deroo T, et al. Soluble recombinant influenza vaccines[J]. Phil Trans R Soc Lond B Biol Sci, 2001, 356(1416):1961-1963.
[69] Ghedin E, Sengamalay N, Shumway M, et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution[J]. Nature, 2005, 437(7062):1162-1166.
[70] Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins[J]. Virology, 2005, 342(2):215-227.
[71] Liu WL, Zou P, Ding J, et al. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design[J]. Microbes Infect, 2005, 7(2):171-177.
[72] Zebedee SL, Lamb RA. Influenza A virus M2 protein:monoclonal antibody restriction of virus growth and detection of M2 in virions[J]. J Virol, 1988, 62(8): 2762-2772.
[73] Treanor JJ, Tierney EL, Zebedee SL, et al. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice[J]. JVirol, 1990, 64(3):1399-1402.
[74] Joshua A, Ralph PB, Lichun D, et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines[J]. J Virol, 2002, 76(9):4536-4546.
[75] Okuda K, Ihata A, Watabe S, et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene[J]. Vaccine, 2001, 19(27):3681-3691.
[76] Heinen PP, Rijsewijk FA, de Boer-LuOtze EA, et a1. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus[J]. J Gen Virol, 2002, 83(8):1851-1859.
[77] Kemble G, Greenberg H. Novel generations of influenza vaccines[J]. Vaccine, 2003, 21(16):1789-1795.
[78] Zhang M, Zharikova BD, Mozdzanowskab K. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus[J]. Mol Immunol, 2006, 43(14):2195-2206.
[79]万春和,刘明. A型流感病毒M2蛋白研究进展[J].动物医学进展, 2007, 28(7):56-60.
[80] Mozdzanowska K, Feng JQ, Eid M, et a1. Induction of influenza type A virus specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2[J]. Vaccine, 2003, 21(20):2616-2626.
[81] Fan J, Liang X, Horton MS, et a1. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice,ferrets and rhesus monkeys[J]. Vaccine, 2004, 22(23): 2993-3003.
[82] Liu WL, Li H, ChenYH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication[J]. FEMS Immunol Med Mic, 2003, 35(2):141 -146.
[83] Liu WL, Zou P, Liu ZQ, et al. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity[J]. Vaccine, 2004, 23(3):366-371.
[84] Zou P, Liu WL, Chen YH. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection[J].Int Immunopharmacol, 2005, 5(4):631-635.
[85] Slepushkin VA, Katz JM, Black RA, et a1. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expresed M2 protein[J]. Vaccine, 1999, 17(18):2237-2244.
[86] Frace AM, Klimov AI, Rowe T, et al. Modified M2 proteins produce heterotypic immunity against influenza A virus[J].Vaccine, 1999, 17(18):2237-2244.
[87] Hahnenberger KM, Krystal M, Esposito K. et a1. Use of microphysiometry for analysis of heterologous ion channels expressed in yeast[J]. Nat Biotechnol, 1996, 14(7):880-883.
[88] Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein[J]. Nat Med, 1999, 15(10):1157-1163.
[89]张立国,曾革非,董婕,等.流行性感冒病毒M2蛋白可溶性表达及其免疫原性的研究[J].病毒学报, 2001, 17(4):318-321.
[90]郑丽舒,段招军. A型流感病毒M2蛋白疫苗的研究进展[J].病毒学报, 2006, 22(6):488-491.
[91] Ernst WA, Kim HJ, Tumpey TM, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines[J]. Vaccine, 2006, 24(24):5158-5168.
[92] De Filette M, Ramne A, Birkett A, et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection[J]. Vaccine, 2006, 24(5):544-551.
[93]杨晓芳,江滟,李婉宜,等.甲型流感病毒M2e与CTB基因融合表达及其免疫特性初步研究[J].细胞与分子免疫学杂志, 2008, 24(3):263-266.
[94] Watanabe T, Watanabe S, Ito H, et a1. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activitv[J]. J Virol, 2001, 75(12): 5656-5662.
[95] Watanabe T, Watanabe S, Kida H, et a1. Influenza A virus with defective M2 ion channel activity as a live vaccine[J]. Virology, 2002, 299(2):266-270.
[96] Jegerlchner A, Schimitz N, Storni T, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody -dependent NK cell activity[J]. J Immunol, 2004, 172(9):5598-5605.
[97] Schotsaert M, De Filette M, Fiers W, et al. Universal M2 ectodomain-basedinfluenza A vaccines: preclinical and clinical developments[J]. Expert Rev Vaccines, 2009, 8(4):499-508.
[98] He XM, Carter DC. Atomic structure and chemistry of human serum album[J]. Nature, 1992, 358(6383):209-215.
[99] Rosenoer VM, Oratz M, Rothschild MA. Albumin Structure,unction and uses[M]. Oxford: pergamon press, 1997.
[100]郭美锦,储炬,杭海峰,等.重组人血清白蛋白表达研究进展[J].生物工程进展, 2000, 20(5):39-42.
[101]黄志明,郭美锦,储炬,等.重组人血清白蛋白发酵过程生长期的代谢计算[J].生物工程学报, 2000, 16(5):631-635.
[102]Vermeulen JN, Meijer DK, Over J, et al. A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor[J]. Antivir Ther, 2007, 12(2):273-278.
[103]Wolff D, Frei E, Hofmeister N, et al. Methotrexate-albumin and aminopterin -albumin effectively prevent experimental acute graft-versus-host disease[J]. Transplantation, 2006, 82(4):527-533.
[104]马大龙.生物技术药物[M].北京:科学出版社, 2001.
[105]Ma SF, Anraku M, Iwao Y, et al. Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites[J]. Drug Metab Dispos, 2005, 33(12):1911-1919.
[106] Ulrich KH, Victort GC, Masaki O. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin[J]. Biol Pharm Bull, 2002, 25(6): 695-704.
[107]Matsushita S, Isima Y, Chuang VT, et al. Functional analysis of recombinant human serum albumin domains for pharmaceutical applications[J]. Pharm Res, 2004, 21(10):1924-1932.
[108]张惠展.基因工程概论[M].上海:华东理工大学出版社, 1999.
[109]刘彦丽,刘永东,王艳辉,等.毕赤酵母发酵生产重组人血清白蛋白高密度培养条件的研究[J].北京化工大学学报, 2003, 30(4):25-28.
[110]Lawn RM, Adehnan J, Bock SC, et al. The sequence of human serum albumin cDNA and its expression in E.coli[J]. Nucleic Acids Res, 1981, 9(22): 6103-6144.
[111] Quirk AV,Geisow MJ,Woodrow JR, et al. Production of recombinant human serum albumin from Saccharomyces cerevisiae[J]. Biotechnol Appl Bioc, 1989, 11(3):273-287.
[112]黄英,黄缨,黄赞,等.山羊β-酪蛋白基因启动区指导人血清白蛋白在转基因小鼠乳汁中的高效表达[J].科学通报, 2000, 45(19):2081-2085.
[113]Barr KA, Hopkins SA, Sreekrisbna K. Protocol for efficient secretion of HSA developed from pichia pastoris[J]. Pharm Eng, 1992, 12(1):48-51.
[114]陈琳,赵艳华,马平,等.重组人血清白蛋白在酵母中的表达及分析鉴定[J].军事医学科学院院刊, 2001, 25(3):202-204.
[115] Kobayashi K, Nakamura N, Sumi A, et al. The development of recombinant human serum albumin[J]. The Apher, 1998, 2(4):257-262.
[116]于在林,富岩.高效表达人血清白蛋白酵母菌株的构建及发酵纯化工艺:中国, 1618967A[P]. 2004-08-27.
[117]Saunders CW, Schmidt BJ, Mallonee RL, et al. Secretion of human serum albumin from Bacillus subtilis [J]. J Bacteriol, 1987, 169(7):2917-2925.
[118] Digan. Secretion of heterologous proteins from the methylotrophic yeast, Pichia pastoris[J]. Devel in Indust Microbio, 1988, 29(Supp 3):59-65.
[119] Kotikanyadan S, Juerg FT, Gregory PT, et a1. Expression of human Serum in Pichia pastoris: United States, 5707828[P]. 1998-01-13.
[120]Chuang VT, Otagiri M. Recombinant human serum albumin[J]. Drugs Today (Barc), 2007, 43(8):547-561.
[121]Kobayashi K. Summary of recombinant human serum albumin development[J]. Biologicals, 2006, 34(1):55-59.
[122]Heo JH, Hong WK, Cho EY, et al. Properties of the Hansenula polymorpha- derived constitutive GAP promoter,assessed using an HSA reporter gene[J]. FEMS Yeast Res, 2003, 4(2):175-184.
[123] Macauley PS, Fazenda ML, Mcneil B, et al. Heterologous protein production using the Pichia pastoris expression system[J]. Yeast, 2005, 22(4):249-270.
[124] Apte-Deshpande A, Rewanwar S, Kotwal P, et al. Efficient expression and secretion of recombinant human growth hormone in the methylotrophic yeast Pichia pastoris: potential applications for other proteins[J]. Biotechnol Appl Biochem, 2009, 54(4):197-205.
[125]满初日嘎,张英霞,张云.重组人血清白蛋白的研究进展[J].生物医学工程学杂志, 2009, 26(4):900-903.
[126]Ohya T, Ohyama M, Kobayashi K. Optimization of human serum albumin production in methylotrophic yeast Pichia pastoris by repeated fed-batch fermentation[J]. Biotechnol Bioeng, 2005, 90(7):876-887.
[127]Shani M, Barash I, Nathan M, et al. Expression of human serum albumin in the milk of transgenic mice[J]. Transgenic Res, 1992, 1(5):195-208.
[128]Ilan N, Barash I, Faerman A. Dual regulation of beta-lactoglobulin/human serum albumin gene expression by extracellular matrix in mammary cells from transgenic mice[J]. Exp Cell Res, 1996, 224(1):28-38.
[129]黄淑帧,黄英,曾溢滔,等.转人血清白蛋白基因试管牛的研究[J].遗传学报, 2000, 27(7):573-579.
[130]Sijmons PC, Dekker BM, Hoekema A, et al. Production of correctly processed human serum albumin in transgenic plants[J]. Biotechonlogy, 1990, 8(3): 217-221.
[131]Farran I, Sanchez-Serrano JJ, Medina JF, et al. Targeted expression of human serum albumin to potato tubers[J]. Transgenic Res, 2002, 11(4):337-346.
[132]Ogawa S, Tomita M, Shimizu K, et al. Generation of a transgenic silkworm that secretes recombinant proteins in the sericin layer of cocoon: production of recombinant human serum albumin[J]. J Biotechnol, 2007, 128(3):531-544.
[133]Yeh P, Landais D, Lemaitrem, et al. Design of yeast-secreted albumin derivatives for human therapy:biological and antiviral propertiesof a serum albumin-CD4 genetic conjugate[J]. Proc Nat1 Acad Sci USA, 1992, 89(5): 1904-1908.
[134]Huang YS, Chen Z, Yang ZY, et al. Preparation and characterization of a potent,long-lasting recombinant human serum albumin-interferon-α2b fusion protein expressed in Pichia pastoris[J]. Eur J Pharm Biopharm, 2007, 67(2): 301-308.
[135]Melder RJ, Osborn BL, Riccobene T, et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice[J]. Cancer Immunol Immunother, 2005, 54(6):535-547.
[136]Halpern W, Riccobene TA, Agostini H, et al. Albugranin, a recombinant humangranulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys[J]. Pharm Res, 2002, 19(11):1720-1729.
[137]Osborn BL, Sekut L, Corcoran M, et al. Albutropin:a growth-hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys[J]. Eur J Pharm, 2002, 456(1/3):149-158.
[138]Dou WF, Lei JY, Zhang LF, et al. Expression,purification,and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris[J]. Protein Expr Purif, 2008, 61(1):45-49.
[139]Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure[J]. Pharm Res, 2004, 21(11):2105-2111.
[140]Duttaroy A, Kanakaraj P, Osborn B L, et al.Development of a long-acting insulin analog using albumin fusion technology[J]. Diabetes, 2005, 54(1): 251-258.
[141]Zhao HL, Xue C, Wang Y, et al. Circumventing the heterogeneity and instability of human serum albumin-interferon-α2b fusion protein by altering its orientation[J]. J Biotechnol, 2007, 131(3):245-252.
[142]汪家政,范明.蛋白质技术手册[M].北京:科学出版社, 2000.
[143] Osborn BL, Olsen HS, Nardelli B, et al. Phannacokinetic and pharmacodynamic studies of a human serum albumin-interferon-αfusion protein in Cynomolgus monkeys[J]. J Pharm Exp Ther, 2002, 303(2):540-548.
[144] Mu XP, Kong N, Chen WL, et al. High-level expression, purification and characterization of recombinant human basic fibroblast growth factor in Pichia pastoris. Protein Expr Purif, 2008(59):282-288.
[145] Clare JJ, Rayment FB, Ballantine SP, et al. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene[J]. Biotechnology, 1991, 9(5):455-460.
[146]朱剑昆,许志祥,黄伟达,等.人重组白细胞介素Ⅱ在毕赤酵母系统中的表达及纯化[J].中国医学科学院学报, 2001, 23(2):127-131.
[147]Kobayashi K, Kuwae S, Ohya T, et al. High-level expression of recombinanthuman serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation[J]. J Biosci Bioeng, 2000, 89(1): 55-61.
[148]Choi BK, Jiménez-Flores R. Expression and purification of glycosylated bovine beta-casein (L70S/P71S) in Pichia pastoris[J]. J Agric Food Chem, 2001, 49(4): 1761-1766.
[149]Sue MP, Mariana L, Fazenda, et al. Heterologous protein production using the Pichia pastoris expression system[J]. Yeast, 2005, 22(4):249-270.
[150]Hughey PG, Roberts PC, Holsinger LJ, et al. Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly[J]. Virology, 1995, 212(2):411-421.
[151]Singh M, O’hagan D. Advances in vaccine adjuvant[J]. Nat Biotechno, 1999, 17(11):1075-1081.
[152]Operschall E, Schuh T, Heinzerling L, et al. Enhanced protection against viral infection by co-administration of phasmid DNA coding for viral antigen and cytoklnes in mice[J]. J Clin Virol, 1999, 13(122):17-27.
[2]金奇.医学分子病毒学[M].北京:科学出版社, 2001.
[3] Fouchier RAM, Munster V, Wallensten A, et al. Characterization of a noval influenza A virus hemagglutinin subtybe (H16) obtained from black-headed gulls[J]. JVirol, 2005, 79(5):2814-2822.
[4] Maeda Y, Horimoto T, Kawaoka Y. Classification and genome structure of influenza virus[J]. Nippon Rinsho, 2003, 61(11):1897-1901.
[5] Joost Haasnoot PC, Cupac D, Berkhout B.Inhibition of virus replication by RNA interference[J]. J Biomed Sci, 2003, 10(6):607-616.
[6] Shvartsman DE, Kotler M, Tall RD, et al. Differently anchored influenza hemagglutinin mutants display distinct inter-action dynamics with mutual rafts[J]. J Cell Biol, 2003, 163 (4):879-888.
[7] Steinhauer DA, Skehel JJ. Genetics of influenza viruses[J]. Annu Rev Genet, 2002, 36:305-332.
[8] Skehel JJ, Wiley DC. Influenza haemagglutinin[J]. Vaccine, 2002, 20(suppl): s51-s54.
[9] Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine[J]. Vaccine, 1999, 17(15-16):2073-2080.
[10] Nakajima K. The mechanism of antigenic shift and drift of human influenza virus[J]. Nippon Rinsho, 2003, 61(11):1897-1903.
[11]宋晓国,王国华,朱翠侠,等.甲型H1N1流感病毒NA、PB2和PA表位抗原区段的克隆和表达[J].生物技术通讯, 2010, 21(1):17-21.
[12] Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009[J]. MMWR Morb Mortal Wkly Rep, 2009, 58(17):467-470.
[13]高和.流感疫苗的研究与应用[J].解放军保健医学杂志, 2004, 6(4):244-245.
[14]陈秀英,戴宏琛.流感的流行及防治的现状研究[J].预防医学情报杂志,2002, 18(4):300-301.
[15] Brede HD. Influenza vaccines[J]. Int Arch Allergy Immunol, 1995, 108(4): 318-320.
[16] Nicholson KG, Wood JM, Zambon M, et al. Influenza[J]. Lancet, 2003, 362 (9397):1733-1745.
[17]苏晓晓,许可,金红.流感病毒疫苗研究的新进展[J].日本医学介绍, 2006, 27(9):424-426.
[18] World Health Organization. Recommendations for production and control of influenza vaccine (inactivated) [C]. 54th Meeting of the WHO Expert Commtttee on Biological Standardization, November 17-21, 2003.
[19]张延龄,张辉.疫苗学[M].北京:科学出版社, 2006.
[20]戚凤春,盛军.流感疫苗的研究进展[J].中国生物制品学杂志, 2004, 17(3): 190-192.
[21] Tolpin MD, Massicot JG, Mullinix MG, et al. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo[J]. Virology, 1981, 112 (2):505-517.
[22] Wareing MD, Tannock GA. Live attenuated vaccines against influenza;an historical review[J]. Vaccine, 2001, 19(25-26):3320-3330.
[23]张英伟,李卫东,马娜,等.以重配技术制备H1N1流感病毒Vero细胞适应株[J].中国生物制品学杂志, 2009, 22(6):529-532.
[24] Treanor JJ, Tierney EL, London WT, et al. Characterisation of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during in vitro production of avian-human reassortant vaccine viruses and after replication in humans and primates[J]. Vaccine, 1991, 9(7):495-501.
[25] Klimov AI, Cox NJ, Yotov WV, et al. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57(H2N2) virus[J]. Virology, 1992, 186(2):795-797.
[26] Belshe RB, Nichol KL, Black SB, et al. Safety,efficacy and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years[J]. Clin Infect Dis, 2004, 39(7):920-927.
[27] Beyer WE, Palache AM, de Jong JC, et al.Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemicantibody response, and vaccine efficacy: A meta-analysis[J]. Vaccine, 2002, 20 (9-10):1340-1353.
[28] Jefferson T, Smith S, Demicheli V, et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children[J]. Lancet, 2005, 365(9461):773-780.
[29] Kemble G, Greenberg H. Novel generations of influenza vaccines[J]. Vaccine, 2003, 21(16):1789-1795.
[30] Romanova JR, Tannock GA, Alexandrova GI. Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses[J]. Vaccine, 1997, 15(6-7):653-658.
[31] Harper SA, Fukuda K, Cox NJ, et al. Using live,attenuated influenza vaccine for prevention and control of influenza:supplemental recommendations of the Advisory Committee on Immunization Practices(ACIP) [J]. MMWR Recomm Rep, 2003, 52 (RR-13):1-8.
[32] Masic A, Babiukt LA, Zhou Y. Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs[J]. J Gen Virol, 2009, 90(Pt2): 375-385.
[33] Garcy’a-Sastre A, Egorov A, Matassov D, et al. Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems[J]. Virology, 1998, 252(2): 324-330.
[34] Watanabe T, Watanabe S, Neumann G, et al. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like Particles[J]. J Virol, 2002, 76(2):767-773.
[35] Talon J, Salvatore M, O′Neill RE, et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach[J]. Proc Natl Acad Sci USA, 2000, 97(8):4309-4314.
[36] Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein[J]. Science, 1993, 259(5102):1745-1749.
[37] Robinson HL, Hunt LA, Webster R G. Protection against a lethal influenza virus challenge by immunization with a hemagglutinin-expressing plasmid DNA[J]. Vaccine, 1993, 11(9):957-960.
[38] Mccluskie MJ, Davis HL. Novel strategies using DNA for the induction ofmucosal immunity[J]. Crit Rev Immunnol, 1999, 19(4):303-329.
[39] Ulmer JB, Deck RR, Dewitt CM, et al. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines[J]. Vaccine, 1994, 12 (16):1541-1544.
[40] Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations[J]. Proc Natl Acad Sci USA, 1993, 90(24):11478-11482.
[41] Tao P, Luo M, Pan Z, et al. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice[J]. Antiviral Res, 2009, 81(3):253-260.
[42] Ulmer JB, Fu TM, Deck RR, et al. Protective CD4+ and CD8+ T cells against influenza induced by vaccination with nucleoprotein DNA[J]. J Virol, 1998, 72(7):5648-5653.
[43] Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines[J]. Vaccine, 200l, 19(6):2666-2672.
[44]王斌. ISCOMATRIXTM佐剂:细胞和体液免疫应答的有效诱导剂[J].国外医学:预防、诊断、治疗用生物制品分册, 2005, 28(5):204-207.
[45] Watanabe I, Hagiwara Y, Kadowaki SE, et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K) [J]. Vaccine, 2002, 20 (29-30):3443-3455.
[46] Glueck R. Review of intranasal influenza vaccine[J]. Adv Drug Deli Rev, 2001, 51(1-3):203-211.
[47]邹丽容,方芳,陈则. IL-12增强流感血凝素DNA疫苗在小鼠中抗流感作用[J].微生物学杂志, 2004, 24(5):11-16.
[48] Hayashi M, Satou E, Ueki R, et al. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator[J]. Biochem Biophys Res Commun, 2005, 329(1):230-236.
[49] Li GX, Tian ZJ, Tong GZ, et al. Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus[J]. Res Vet Sci, 2009, 86(3): 406-413.
[50] Watabe S, Xin KQ, Ihata A, et al. Protection against influenza virus challenge bytopical application of influenza DNA vaccine[J]. Vaccine, 2001, 19(31): 4434 -4444.
[51] Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization:the possible role of DNA uptake in the induction of cellular immunity to viruses[J]. Proc Natl Acad Sci USA, 1994, 91(20):9519-9523.
[52] Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors[J]. DNA Cell Biol, 1993, 12(9):777-783.
[53] Robinson HL, Boyle CA, Feltquate DM, et al. DNA immunization for influenza virus:studies using hemagglutinin- and nucleoprotein-expressing DNAs[J]. J Infect Dis, 1997, 176(suppl 1):S50-S55.
[54] Chen Z, Yoshikawa T, Kadowaki S, et al. Protection and antibody response in different strains of mouse immunized with plasmid DNAs encoding influenza virus hemagglutinin, neuraminidase and nucleoprotein[J]. J Gen Virol, 1999, 80(10):2559-2564.
[55] Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface[J]. Cell, 1985, 40(3): 627-633.
[56] Sakaguchi T, Tu Q, Pinto LH, et a1. The active aligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer[J]. Proc Natl Acad Sci USA, 1997, 94(5):5000-5004.
[57] Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity[J]. Cell, 1992, 69(3):517-528.
[58] Czabotar PE, Martin SR, Hay AJ. Studies of structural changes in the M2 proton channel of influenza A virus by tryptophan fluorescence[J].Virus Res, 2004, 99(1):57-61.
[59] Duong-Ly KC, Nanda V, Degrado WF, et al. The conformation of the pore region of the M2 proton channel dependson lipid bilayer environment[J]. Protein Sci, 2005, 14(4):856-861.
[60] Kass I, Arkin IT. How pH opens a H+ channel: the gating mechanism of infiuenza A M2[J]. Structure, 2005, 13(12):1789-1798.
[61] Wu Y, Voth GA. A computational study of the closed and open states of the influenza a M2 proton channel[J]. Biophys J, 2005, 88(4):2402-2411.
[62] Castrucci MR, Kawaoka Y. Reverse genetics system for generation of an influenza a virus mutant containing a deletion of the carboxylterminal residue of M2 protein[J]. J Virol, 1995, 69(5):2725-2728.
[63] Monto AS. The role of antivirals in the control of influenza[J]. Vaccine, 2003, 21(16):1796-1800.
[64] Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection[J]. J Virol, 1988, 62(5): 1508-1512.
[65] Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults:systematic review[J]. Lancet, 2006, 367(24):303-313.
[66] Kitahori Y, Nakano M, Inoue Y. Frequency of amantadine-resistant influenza A virus isolated from 2001-02 to 2004-05 in Nara Prefecture[J]. Jpn J Infect Dis, 2006, 59(3):197-199.
[67] Masuda H, Suzuki H, Oshitani H, et al. Incidence of amantadine-resistant influenza a viruses in sentinel surveillance sites and nursing homes in Niigata, Japan[J]. Microbiol Immunol, 2000, 44 (10):833-839.
[68] Fiers W, Neirynck S, Deroo T, et al. Soluble recombinant influenza vaccines[J]. Phil Trans R Soc Lond B Biol Sci, 2001, 356(1416):1961-1963.
[69] Ghedin E, Sengamalay N, Shumway M, et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution[J]. Nature, 2005, 437(7062):1162-1166.
[70] Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins[J]. Virology, 2005, 342(2):215-227.
[71] Liu WL, Zou P, Ding J, et al. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design[J]. Microbes Infect, 2005, 7(2):171-177.
[72] Zebedee SL, Lamb RA. Influenza A virus M2 protein:monoclonal antibody restriction of virus growth and detection of M2 in virions[J]. J Virol, 1988, 62(8): 2762-2772.
[73] Treanor JJ, Tierney EL, Zebedee SL, et al. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice[J]. JVirol, 1990, 64(3):1399-1402.
[74] Joshua A, Ralph PB, Lichun D, et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines[J]. J Virol, 2002, 76(9):4536-4546.
[75] Okuda K, Ihata A, Watabe S, et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene[J]. Vaccine, 2001, 19(27):3681-3691.
[76] Heinen PP, Rijsewijk FA, de Boer-LuOtze EA, et a1. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus[J]. J Gen Virol, 2002, 83(8):1851-1859.
[77] Kemble G, Greenberg H. Novel generations of influenza vaccines[J]. Vaccine, 2003, 21(16):1789-1795.
[78] Zhang M, Zharikova BD, Mozdzanowskab K. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus[J]. Mol Immunol, 2006, 43(14):2195-2206.
[79]万春和,刘明. A型流感病毒M2蛋白研究进展[J].动物医学进展, 2007, 28(7):56-60.
[80] Mozdzanowska K, Feng JQ, Eid M, et a1. Induction of influenza type A virus specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2[J]. Vaccine, 2003, 21(20):2616-2626.
[81] Fan J, Liang X, Horton MS, et a1. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice,ferrets and rhesus monkeys[J]. Vaccine, 2004, 22(23): 2993-3003.
[82] Liu WL, Li H, ChenYH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication[J]. FEMS Immunol Med Mic, 2003, 35(2):141 -146.
[83] Liu WL, Zou P, Liu ZQ, et al. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity[J]. Vaccine, 2004, 23(3):366-371.
[84] Zou P, Liu WL, Chen YH. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection[J].Int Immunopharmacol, 2005, 5(4):631-635.
[85] Slepushkin VA, Katz JM, Black RA, et a1. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expresed M2 protein[J]. Vaccine, 1999, 17(18):2237-2244.
[86] Frace AM, Klimov AI, Rowe T, et al. Modified M2 proteins produce heterotypic immunity against influenza A virus[J].Vaccine, 1999, 17(18):2237-2244.
[87] Hahnenberger KM, Krystal M, Esposito K. et a1. Use of microphysiometry for analysis of heterologous ion channels expressed in yeast[J]. Nat Biotechnol, 1996, 14(7):880-883.
[88] Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein[J]. Nat Med, 1999, 15(10):1157-1163.
[89]张立国,曾革非,董婕,等.流行性感冒病毒M2蛋白可溶性表达及其免疫原性的研究[J].病毒学报, 2001, 17(4):318-321.
[90]郑丽舒,段招军. A型流感病毒M2蛋白疫苗的研究进展[J].病毒学报, 2006, 22(6):488-491.
[91] Ernst WA, Kim HJ, Tumpey TM, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines[J]. Vaccine, 2006, 24(24):5158-5168.
[92] De Filette M, Ramne A, Birkett A, et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection[J]. Vaccine, 2006, 24(5):544-551.
[93]杨晓芳,江滟,李婉宜,等.甲型流感病毒M2e与CTB基因融合表达及其免疫特性初步研究[J].细胞与分子免疫学杂志, 2008, 24(3):263-266.
[94] Watanabe T, Watanabe S, Ito H, et a1. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activitv[J]. J Virol, 2001, 75(12): 5656-5662.
[95] Watanabe T, Watanabe S, Kida H, et a1. Influenza A virus with defective M2 ion channel activity as a live vaccine[J]. Virology, 2002, 299(2):266-270.
[96] Jegerlchner A, Schimitz N, Storni T, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody -dependent NK cell activity[J]. J Immunol, 2004, 172(9):5598-5605.
[97] Schotsaert M, De Filette M, Fiers W, et al. Universal M2 ectodomain-basedinfluenza A vaccines: preclinical and clinical developments[J]. Expert Rev Vaccines, 2009, 8(4):499-508.
[98] He XM, Carter DC. Atomic structure and chemistry of human serum album[J]. Nature, 1992, 358(6383):209-215.
[99] Rosenoer VM, Oratz M, Rothschild MA. Albumin Structure,unction and uses[M]. Oxford: pergamon press, 1997.
[100]郭美锦,储炬,杭海峰,等.重组人血清白蛋白表达研究进展[J].生物工程进展, 2000, 20(5):39-42.
[101]黄志明,郭美锦,储炬,等.重组人血清白蛋白发酵过程生长期的代谢计算[J].生物工程学报, 2000, 16(5):631-635.
[102]Vermeulen JN, Meijer DK, Over J, et al. A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor[J]. Antivir Ther, 2007, 12(2):273-278.
[103]Wolff D, Frei E, Hofmeister N, et al. Methotrexate-albumin and aminopterin -albumin effectively prevent experimental acute graft-versus-host disease[J]. Transplantation, 2006, 82(4):527-533.
[104]马大龙.生物技术药物[M].北京:科学出版社, 2001.
[105]Ma SF, Anraku M, Iwao Y, et al. Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites[J]. Drug Metab Dispos, 2005, 33(12):1911-1919.
[106] Ulrich KH, Victort GC, Masaki O. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin[J]. Biol Pharm Bull, 2002, 25(6): 695-704.
[107]Matsushita S, Isima Y, Chuang VT, et al. Functional analysis of recombinant human serum albumin domains for pharmaceutical applications[J]. Pharm Res, 2004, 21(10):1924-1932.
[108]张惠展.基因工程概论[M].上海:华东理工大学出版社, 1999.
[109]刘彦丽,刘永东,王艳辉,等.毕赤酵母发酵生产重组人血清白蛋白高密度培养条件的研究[J].北京化工大学学报, 2003, 30(4):25-28.
[110]Lawn RM, Adehnan J, Bock SC, et al. The sequence of human serum albumin cDNA and its expression in E.coli[J]. Nucleic Acids Res, 1981, 9(22): 6103-6144.
[111] Quirk AV,Geisow MJ,Woodrow JR, et al. Production of recombinant human serum albumin from Saccharomyces cerevisiae[J]. Biotechnol Appl Bioc, 1989, 11(3):273-287.
[112]黄英,黄缨,黄赞,等.山羊β-酪蛋白基因启动区指导人血清白蛋白在转基因小鼠乳汁中的高效表达[J].科学通报, 2000, 45(19):2081-2085.
[113]Barr KA, Hopkins SA, Sreekrisbna K. Protocol for efficient secretion of HSA developed from pichia pastoris[J]. Pharm Eng, 1992, 12(1):48-51.
[114]陈琳,赵艳华,马平,等.重组人血清白蛋白在酵母中的表达及分析鉴定[J].军事医学科学院院刊, 2001, 25(3):202-204.
[115] Kobayashi K, Nakamura N, Sumi A, et al. The development of recombinant human serum albumin[J]. The Apher, 1998, 2(4):257-262.
[116]于在林,富岩.高效表达人血清白蛋白酵母菌株的构建及发酵纯化工艺:中国, 1618967A[P]. 2004-08-27.
[117]Saunders CW, Schmidt BJ, Mallonee RL, et al. Secretion of human serum albumin from Bacillus subtilis [J]. J Bacteriol, 1987, 169(7):2917-2925.
[118] Digan. Secretion of heterologous proteins from the methylotrophic yeast, Pichia pastoris[J]. Devel in Indust Microbio, 1988, 29(Supp 3):59-65.
[119] Kotikanyadan S, Juerg FT, Gregory PT, et a1. Expression of human Serum in Pichia pastoris: United States, 5707828[P]. 1998-01-13.
[120]Chuang VT, Otagiri M. Recombinant human serum albumin[J]. Drugs Today (Barc), 2007, 43(8):547-561.
[121]Kobayashi K. Summary of recombinant human serum albumin development[J]. Biologicals, 2006, 34(1):55-59.
[122]Heo JH, Hong WK, Cho EY, et al. Properties of the Hansenula polymorpha- derived constitutive GAP promoter,assessed using an HSA reporter gene[J]. FEMS Yeast Res, 2003, 4(2):175-184.
[123] Macauley PS, Fazenda ML, Mcneil B, et al. Heterologous protein production using the Pichia pastoris expression system[J]. Yeast, 2005, 22(4):249-270.
[124] Apte-Deshpande A, Rewanwar S, Kotwal P, et al. Efficient expression and secretion of recombinant human growth hormone in the methylotrophic yeast Pichia pastoris: potential applications for other proteins[J]. Biotechnol Appl Biochem, 2009, 54(4):197-205.
[125]满初日嘎,张英霞,张云.重组人血清白蛋白的研究进展[J].生物医学工程学杂志, 2009, 26(4):900-903.
[126]Ohya T, Ohyama M, Kobayashi K. Optimization of human serum albumin production in methylotrophic yeast Pichia pastoris by repeated fed-batch fermentation[J]. Biotechnol Bioeng, 2005, 90(7):876-887.
[127]Shani M, Barash I, Nathan M, et al. Expression of human serum albumin in the milk of transgenic mice[J]. Transgenic Res, 1992, 1(5):195-208.
[128]Ilan N, Barash I, Faerman A. Dual regulation of beta-lactoglobulin/human serum albumin gene expression by extracellular matrix in mammary cells from transgenic mice[J]. Exp Cell Res, 1996, 224(1):28-38.
[129]黄淑帧,黄英,曾溢滔,等.转人血清白蛋白基因试管牛的研究[J].遗传学报, 2000, 27(7):573-579.
[130]Sijmons PC, Dekker BM, Hoekema A, et al. Production of correctly processed human serum albumin in transgenic plants[J]. Biotechonlogy, 1990, 8(3): 217-221.
[131]Farran I, Sanchez-Serrano JJ, Medina JF, et al. Targeted expression of human serum albumin to potato tubers[J]. Transgenic Res, 2002, 11(4):337-346.
[132]Ogawa S, Tomita M, Shimizu K, et al. Generation of a transgenic silkworm that secretes recombinant proteins in the sericin layer of cocoon: production of recombinant human serum albumin[J]. J Biotechnol, 2007, 128(3):531-544.
[133]Yeh P, Landais D, Lemaitrem, et al. Design of yeast-secreted albumin derivatives for human therapy:biological and antiviral propertiesof a serum albumin-CD4 genetic conjugate[J]. Proc Nat1 Acad Sci USA, 1992, 89(5): 1904-1908.
[134]Huang YS, Chen Z, Yang ZY, et al. Preparation and characterization of a potent,long-lasting recombinant human serum albumin-interferon-α2b fusion protein expressed in Pichia pastoris[J]. Eur J Pharm Biopharm, 2007, 67(2): 301-308.
[135]Melder RJ, Osborn BL, Riccobene T, et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice[J]. Cancer Immunol Immunother, 2005, 54(6):535-547.
[136]Halpern W, Riccobene TA, Agostini H, et al. Albugranin, a recombinant humangranulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys[J]. Pharm Res, 2002, 19(11):1720-1729.
[137]Osborn BL, Sekut L, Corcoran M, et al. Albutropin:a growth-hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys[J]. Eur J Pharm, 2002, 456(1/3):149-158.
[138]Dou WF, Lei JY, Zhang LF, et al. Expression,purification,and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris[J]. Protein Expr Purif, 2008, 61(1):45-49.
[139]Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure[J]. Pharm Res, 2004, 21(11):2105-2111.
[140]Duttaroy A, Kanakaraj P, Osborn B L, et al.Development of a long-acting insulin analog using albumin fusion technology[J]. Diabetes, 2005, 54(1): 251-258.
[141]Zhao HL, Xue C, Wang Y, et al. Circumventing the heterogeneity and instability of human serum albumin-interferon-α2b fusion protein by altering its orientation[J]. J Biotechnol, 2007, 131(3):245-252.
[142]汪家政,范明.蛋白质技术手册[M].北京:科学出版社, 2000.
[143] Osborn BL, Olsen HS, Nardelli B, et al. Phannacokinetic and pharmacodynamic studies of a human serum albumin-interferon-αfusion protein in Cynomolgus monkeys[J]. J Pharm Exp Ther, 2002, 303(2):540-548.
[144] Mu XP, Kong N, Chen WL, et al. High-level expression, purification and characterization of recombinant human basic fibroblast growth factor in Pichia pastoris. Protein Expr Purif, 2008(59):282-288.
[145] Clare JJ, Rayment FB, Ballantine SP, et al. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene[J]. Biotechnology, 1991, 9(5):455-460.
[146]朱剑昆,许志祥,黄伟达,等.人重组白细胞介素Ⅱ在毕赤酵母系统中的表达及纯化[J].中国医学科学院学报, 2001, 23(2):127-131.
[147]Kobayashi K, Kuwae S, Ohya T, et al. High-level expression of recombinanthuman serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation[J]. J Biosci Bioeng, 2000, 89(1): 55-61.
[148]Choi BK, Jiménez-Flores R. Expression and purification of glycosylated bovine beta-casein (L70S/P71S) in Pichia pastoris[J]. J Agric Food Chem, 2001, 49(4): 1761-1766.
[149]Sue MP, Mariana L, Fazenda, et al. Heterologous protein production using the Pichia pastoris expression system[J]. Yeast, 2005, 22(4):249-270.
[150]Hughey PG, Roberts PC, Holsinger LJ, et al. Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly[J]. Virology, 1995, 212(2):411-421.
[151]Singh M, O’hagan D. Advances in vaccine adjuvant[J]. Nat Biotechno, 1999, 17(11):1075-1081.
[152]Operschall E, Schuh T, Heinzerling L, et al. Enhanced protection against viral infection by co-administration of phasmid DNA coding for viral antigen and cytoklnes in mice[J]. J Clin Virol, 1999, 13(122):17-27.